Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Blood|July 27, 2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani, Ross L Levine, Terra Lasho, et al.
Leukemia|January 8, 2026
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemiaFanny Gonzales, Constanze Schneider, Gabriela Alexe, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Leukemia|August 3, 2021
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapyYana Pikman, Nicole Ocasio-Martinez, Gabriela Alexe, et al.
Cancer Cell|February 15, 2014
SYK is a critical regulator of FLT3 in acute myeloid leukemiaAlexandre Puissant, Nina Fenouille, Gabriela Alexe, et al.
Blood|September 28, 2021
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AMLEmily B Heikamp, Jill A Henrich, Florian Perner, et al.
Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Blood Advances|April 7, 2026
DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid LeukemiaLonneke Verboon, Sonali P Barwe, Meredith Tavenner, et al.
Pageof 6